Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.45 |
| ▸ | HPGD | P15428 | 6/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959276 | 0.99 | ALDH1A1 (0.47) | ALDH1A1HPGDHSD17B10HTTMAPT | |
| SCHEMBL2958030 | 0.93 | ALDH1A1 (0.42) | ALDH1A1HPGDHSD17B10HTTMAPT | |
| SCHEMBL2953084 | 0.90 | ALDH1A1 (0.42) | ALDH1A1HPGDHSD17B10HTTMAPT | |
| SCHEMBL2950110 | 0.90 | TERT (0.37) | ALDH1A1HPGDHSD17B10HTTMAPT | |
| SCHEMBL2956227 | 0.89 | ALDH1A1 (0.43) | ALDH1A1HPGDHSD17B10HTTMAPT | |
| SCHEMBL2958967 | 0.88 | TOP2A (0.39) | ALDH1A1HPGDHSD17B10HTTMAPT | |
| Ammonia Solution, Strong SCHEMBL1267334 | 0.84 | CDK4 (0.38) | ALDH1A1HPGDHSD17B10MAPTALOX15 | |
| SCHEMBL2955571 | 0.83 | ALDH1A1 (0.43) | ALDH1A1HPGDHSD17B10HTTMAPT | |
| SCHEMBL2958436 | 0.83 | KMT2A (0.41) | ALDH1A1HPGDHSD17B10HTTMAPT | |
| SCHEMBL2958575 | 0.83 | CDK4 (0.38) | ALDH1A1HPGDHSD17B10HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423047-B2 | Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2008-09-09 | — | — | US | claimed |
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | UCB PHARMA S.A. (BE) | 2006-01-05 | — | — | US | claimed |
| US-7763729-B2 | Bicyclic heteroaromatic derivatives | UCB PHARMA S.A. (BE) | 2010-07-27 | — | — | US | disclosed |
| US-20090042877-A1 | Bicyclic Heteroaromatic Derivatives | CELLTECH R&D LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-7482452-B2 | Process for preparing 3-aminothienopyridone derivatives | CELLTECH R&D LIMITED (GB) | 2009-01-27 | — | — | US | disclosed |
| EP-1638980-B1 | PROCESS FOR PREPARING 3-AMINOTHIENOPYRIDONE DERIVATIVES | UCB PHARMA SA (BE) | 2008-11-05 | — | — | EP | disclosed |
| US-7423047-B2 | Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2008-09-09 | — | — | US | disclosed |
| US-20070191608-A1 | Process for preparing 3-aminothienopyridone derivatives | CELLTECH R&D LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | UCB PHARMA S.A. (BE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191608-A1 | Process for preparing 3-aminothienopyridone derivatives | MAPK3, MAP3K6, MAP4K1 | ALDH1A1 1970/4885HPGD 1412/4885HSD17B10 3550/4885 |
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | MAPK1, CNKSR1, ALK | ALDH1A1 1045/4885HPGD 3282/4885HSD17B10 2273/4885 |
| US-20090042877-A1 | Bicyclic Heteroaromatic Derivatives | MAPK1, CNKSR1, CBR1 | ALDH1A1 717/4885HPGD 3563/4885HSD17B10 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.